BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics reports a significant increase in median overall survival to 15.6 months for metastatic breast cancer patients treated with Bria-IMT™ in combination with an immune checkpoint inhibitor, outperforming previous literature benchmarks. This promising result is part of their Phase 2 study and contributes to the ongoing Phase 3 clinical trial aimed at establishing a new standard of care.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
